Company announcement – No. 49 / 2020
Original post:
Zealand Pharma grants warrants and restricted share units under the employee warrant program and management long-term incentive program
SAN DIEGO, Sept. 14, 2020 (GLOBE NEWSWIRE) -- Ansun Biopharma, Inc., a clinical stage biopharmaceutical company, today announced the company will present at the H.C. Wainwright & Co. 22nd Annual Global Investment Conference, taking place September 14-16. During the conference, Nancy Chang, Ph.D., chief executive officer of Ansun, will deliver a corporate update to potential investors registered for the meeting. The corporate update will cover recent and upcoming company milestones, as well as detail clinical progress of the company’s lead drug candidate, DAS181, a multi-mechanism recombinant sialidase protein being studied for its potential to treat patients with respiratory diseases, including influenza and parainfluenza, by preventing viral entry into respiratory epithelial cells. Ansun is also assessing DAS181 in patients with severe COVID-19 in Phase 2 studies.
Read the original post:
Ansun Biopharma to Present at H.C. Wainwright & Co. 22nd Annual Global Investment Conference
LYON, France, Sept. 14, 2020 (GLOBE NEWSWIRE) -- Article 223-16 of general regulation of French Autorité des Marchés Financiers Lyon – France
The rest is here:
Monthly information related to total number of voting rights and shares composing the share capital – August 31, 2020
Molecular syndromic test for COVID-19, influenza and other common respiratory pathogenshelps health care professionals prepare for flu season
Here is the original post:
GenMark Diagnostics’ ePlex® Respiratory Pathogen Panel 2 (RP2) achieves CE Mark
BELTSVILLE, Md., Sept. 14, 2020 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the appointment of John G. Houston, Ph.D., to its board of directors as of September 10, 2020. Dr. Houston has more than 30 years of experience in the pharmaceutical and biotech industry and currently serves as president and chief executive officer of Arvinas, Inc. In addition, Judith Li has announced that she is stepping down from the company’s board of directors.
Go here to see the original:
NextCure Announces Appointment of John G. Houston, Ph.D., to its Board of Directors
Company announcement no. 32 - 20 14 September 2020
See the article here:
Private placement of existing shares and major shareholder announcement
Company announcement no. 33 - 20 14 September 2020
Go here to see the original:
Notification of Managers’ transactions
CAMBRIDGE, Mass., Sept. 14, 2020 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, today announced the appointment of Michelle Quinn Smith as Chief Human Resources Officer. Ms. Smith brings over 30 years of experience in human resources to Voyager, including leadership roles at Flagship Pioneering, Takeda Pharmaceuticals, Genzyme, and Sanofi.
See original here:
Voyager Therapeutics Appoints Michelle Quinn Smith as Chief Human Resources Officer
SPARTA, N.J., Sept. 14, 2020 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a late-stage specialty pharmaceutical company focused on developing its clinically-validated and patent-protected PLxGuard™ delivery system to provide more effective and safer products, VAZALORE™ 325 mg and VAZALORE™ 81 mg (referred to together as “VAZALORE”™), announced today that Natasha Giordano, President and Chief Executive Officer, and Rita O’Connor, Chief Financial Officer, will present virtually at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit as follows:
The rest is here:
PLx Pharma Inc. to Present Virtually at Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
